OR WAIT null SECS
December 17, 2025
A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.
Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.
Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.
December 09, 2025
The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand from attendees about challenges and insights from the front lines of amorphous drug development.
November 24, 2025
Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.
October 08, 2025
In this interview, Sandra Reid of gChem explains how PROCIPIENT®, its USP-grade DMSO, is uniquely manufactured under cGMP and ICH Q7 guidelines to ensure compliance, consistency, and quality across global pharmaceutical markets.
In this interview, Rishi Pimentel of gChem explains how PROCIPIENT®, a cGMP-compliant excipient-grade DMSO, supports advanced therapies with superior purity and sterility, mitigates risks of using industrial-grade solvents, and strengthens regulatory readiness and supply chain security.
In this interview, Dr Nigel Langley of gChem discusses the importance of excipient grade, compliance, and supply chain transparency, and introduces PROCIPIENT®, gChem’s high-purity pharmaceutical-grade DMSO.